- Ortho Regenerative Technologies (ORTH) has announced a non-brokered private placement of units for maximum gross proceeds of $3.0 million
- Each unit will be priced at $0.30 and consist of one common share and one share purchase warrant
- Net proceeds will be used for the ORTHO-R Phase I/II US Clinical trial, and general corporate purposes
- The offering is expected to close on or about February 28, 2022
- Ortho is a clinical-stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies
- Ortho Regenerative Technologies Inc. (ORTH) is unchanged, trading at C$0.27 per share at 1:30 pm EST.
Ortho Regenerative Technologies (ORTH) has announced a non-brokered private placement of units for maximum gross proceeds of $3.0 million.
Each unit will be priced at $0.30 and consist of one common share and one share purchase warrant. Each warrant is exercisable into one additional share at the price of $0.50 for a period of 48 months from closing.
Warrants are subject to an acceleration clause.
Net proceeds will be used for the ORTHO-R Phase I/II US Clinical trial, and general corporate purposes.
Shares and warrants will be subject to a statutory 4-month hold period.
The offering is expected to close on or about February 28, 2022, and is subject to the approval of the CSE.
Ortho is a clinical-stage orthobiologics company dedicated to the development of novel therapeutic soft tissue repair technologies.
Ortho Regenerative Technologies Inc. (ORTH) is unchanged, trading at C$0.27 per share at 1:30 pm EST.
